ENG/中
老虎證券
市场
行情
24/7新闻
产品
Cash Boost账户
期权
A股通
港股
固定票息票据
美股
基金超市
美国国债
新加坡股
期货
Tiger BOSS Debit Card
老虎钱袋子
功能
定投
CPF/SRS 投资
专栏
美股碎股
TigerAI
费用
综合账户
股票与ETF
期权、窝轮与牛熊证
期货
债券
基金超市
Cash Boost
股票与ETF
融资利率
活动
帮助
账户操作
如何开户
开户文件
账户类型
资金与转仓
入金
DDA快捷入金
出金
转入股票
转出股票
货币兑换
产品与交易
可交易产品
订单类型
交易规则
申报
融资融券
保证金与杠杆
风险管理
做空风险
基金超市
基金开户与交易
Cash Boost账户
Cash Boost 账户FAQ
如何开通 Cash Boost 账户
如何用Cash Boost 账户交易
如何绑定CDP证券账户
Tiger Boss Debit Card
常见问题
费用说明
如何充值
如何使用我的Debit card
账单报表
账单报表
股息(分红)
机构
Tiger Fund Management
机构服务
财富及资产管理人
自营交易机构
介绍经纪商
三方服务商
老虎API平台
登入
立即註冊
Toggle
美股
詳情
本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務
Militia Long/Short Equity ETF
31.64
+0.1200
0.38%
盤後:
31.63
-0.0100
-0.03%
16:04 EDT
成交量:
10.81萬
成交額:
342.65萬
市值:
1.38億
市盈率:
- -
高:
31.85
開:
31.74
低:
31.61
收:
31.52
52周最高:
32.87
52周最低:
25.63
股本:
436.00萬
流通股本:
431.00萬
量比:
2.38
換手率:
2.51%
股息:
- -
股息率:
- -
淨資產收益率:
--
總資產收益率:
--
市淨率:
--
市盈率(LYR):
- -
資料載入中...
總覽
公司
新聞
公告
安科生物披露創新藥HuA21注射液在2025年歐洲腫瘤內科學會年會公佈臨牀研究數據
格隆汇
·
10/21
FAK賽道處於爆發前夜!應世生物深耕佈局,全球領跑
蓝鲸财经
·
10/14
藥明巨諾:國產病毒載體版倍諾達補充申請獲國家藥監局受理
财中社
·
10/09
創新藥尋突圍,「自研+引入」雙軌戰略能否重塑增長極?
21世纪经济报道
·
09/26
腫瘤耐藥治療賽道破局者:應世生物赴港IPO
格隆汇
·
09/26
盛諾基淫羊藿素軟膠囊新增治療胰腺癌適應症獲臨牀批件
中金财经
·
09/22
重大突破!中國這款新藥,中美官方都認定有突破性療效!世界肺癌大會沸騰了
每日经济新闻
·
09/14
百利天恆iza-bren雙抗ADC獲WCLC雙重認可 一線治療EGFR突變肺癌ORR達100%
金融界
·
09/09
宗艾替尼在華獲批 用於非小細胞肺癌治療
新京报
·
08/29
百億美元BD大藥,國內還有高手
生物制药小编
·
08/28
諾誠健華的下一個黃金十年
生物制药小编
·
08/25
德達博妥單抗在華獲批新適應症,用於晚期乳腺癌治療
新京报
·
08/23
創新成果逐步兑現,全球化佈局潛力可期
东方财富
·
08/20
榮昌生物:國家藥監局授予RC148突破性治療藥物認定用於治療非小細胞肺癌(NSCLC)
格隆汇
·
08/19
2025年(H1)MNC研發動向全景:技術迭代與結構重塑下的新格局
药智网
·
08/19
基石藥業2025年中期業績公告:創新管線加速推進,價值潛力凸顯
基石药业官微
·
08/14
大行評級|花旗:大幅上調復宏漢霖目標價至95港元 評級升至「買入」
格隆汇
·
08/14
復宏漢霖三款創新爆品集中亮相WCLC,出擊肺癌全類型治療最前沿
格隆汇
·
08/14
同源康醫藥-B:EGFR靶向創新藥艾多替尼在腦轉移肺癌患者中展現突破性療效——WCLC 2025公佈ESAONA關鍵註冊研究中期結果
智通财经
·
08/14
業績終迎拐點,股價卻微跌,資本在擔心什麼?
CPHI制药在线
·
08/11
更多
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/ORR/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ORR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","market":"US","secType":"STK","nameCN":"Militia Long/Short Equity ETF","latestPrice":31.64,"timestamp":1761249600000,"preClose":31.52,"halted":0,"volume":108136,"hourTrading":{"tag":"盘后","latestPrice":31.63,"preClose":31.64,"latestTime":"16:04 EDT","volume":1,"amount":31.63,"timestamp":1761249851524},"delay":0,"floatShares":4310000,"shares":4360000,"eps":0,"marketStatus":"盤後交易","change":0.12,"latestTime":"10-23 16:18:57 EDT","open":31.74,"high":31.8485,"low":31.61,"amount":3426477.35722,"amplitude":0.007567,"askPrice":47.47,"askSize":200,"bidPrice":31,"bidSize":80,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1761264000000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":31.52,"sharesOutstanding":4360000,"nav":31.26,"aum":136293600,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":31.63,"preClose":31.64,"latestTime":"16:04 EDT","volume":1,"amount":31.63,"timestamp":1761249851524},"volumeRatio":2.382994},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","floatShares":4310000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":2.382994,"shares":4360000,"dividePrice":0,"high":31.8485,"amplitude":0.007567,"preClose":31.52,"low":31.61,"week52Low":25.63,"pbRate":"--","week52High":32.87,"institutionHeld":0,"latestPrice":31.64,"committee":-0.428571,"eps":0,"divideRate":0,"volume":108136,"delay":0,"ttmEps":0,"open":31.74,"prevYearClose":25.88,"prevWeekClose":31.18,"prevMonthClose":31.475,"prevQuarterClose":31.475,"fiveDayClose":30.9996,"twentyDayClose":32.0026,"sixtyDayClose":29.9947},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ORR\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ORR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ORR\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ORR\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2577639389","title":"安科生物披露創新藥HuA21注射液在2025年歐洲腫瘤內科學會年會公佈臨牀研究數據","url":"https://stock-news.laohu8.com/highlight/detail?id=2577639389","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577639389?lang=zh_tw&edition=fundamental","pubTime":"2025-10-21 08:53","pubTimestamp":1761007995,"startTime":"0","endTime":"0","summary":"格隆汇10月21日丨安科生物公布,公司于2025年10 月 17 日至 21 日在德国柏林召开的欧洲肿瘤内科学会年会上,以壁报形式公布自主研发的生物创新药重组抗 HER2 人源化HuA21 单克隆抗体注射液联合曲妥珠单抗和化疗治疗HER2 阳性晚期胃/胃食管交界处腺癌 Ib/II 期剂量递增和扩展研究的最新研究成果。HuA21 通过诱导 HER2 受体的内吞和下调,打断癌细胞信号通路,从而抑制癌细胞生长和增殖,产生促进癌细胞凋亡、抗肿瘤血管生成等效果,最终达到抑制肿瘤的作用。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251021085601a6c4ac4d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251021085601a6c4ac4d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ORR","BK4181","PK","KG","BK4218","BK4019"],"gpt_icon":0},{"id":"2575701254","title":"FAK賽道處於爆發前夜!應世生物深耕佈局,全球領跑","url":"https://stock-news.laohu8.com/highlight/detail?id=2575701254","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575701254?lang=zh_tw&edition=fundamental","pubTime":"2025-10-14 12:29","pubTimestamp":1760416190,"startTime":"0","endTime":"0","summary":"协同管线布局,拓展治疗边界为巩固赛道领先地位,应世生物还布局了第二代选择性FAK抑制剂IN10028,依托ifebemtinib的研发经验,优化与RAS抑制剂、ADC等疗法的协同效果,计划于2025年第四季度提交IND申请,2026年启动首次人体临床试验。Ifebemtinib有望成为同类最佳的选择性FAK抑制剂,凭借ifebemtinib的先发优势与协同管线布局,应世生物有望在这一蓝海市场中占据领先地位。截至2025年3月末,公司账上的现金及","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1760316553550547598","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK4563","BK4509","BK4171","BK4108","BK4007","TME","BK4224","BK4585","LU0456842615.SGD","LU2039709279.SGD","BK4588","BK4565","IE00BYQNZ168.SGD","PLD","BK4535","PROC","BK4526","LU0359201612.USD","BK4531","BK4548","BK4534","IE00B12V2V27.USD","LU0359202008.SGD","IE00BYTNYN87.SGD","ORR","01698","SG9999011746.SGD","BK4552","BK4571","BK4567","LU1023057109.AUD"],"gpt_icon":0},{"id":"2574538681","title":"藥明巨諾:國產病毒載體版倍諾達補充申請獲國家藥監局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2574538681","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574538681?lang=zh_tw&edition=fundamental","pubTime":"2025-10-09 17:48","pubTimestamp":1760003334,"startTime":"0","endTime":"0","summary":"10月9日,药明巨诺(02126)发布公告,中国国家药品监督管理局已正式受理公司倍诺达?使用国产病毒载体的上市后补充申请。此次申请基于一项II期单臂研究,旨在评估使用新工艺病毒载体(JWLV011)生产的瑞基奥仑赛注射液与现有病毒载体生产的产品可比性。研究结果显示,3个月最佳客观缓解率(ORR)为66.67%,疾病完全缓解率(CR)为41.67%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202510093529591131.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4161","CR","ORR"],"gpt_icon":0},{"id":"2570035010","title":"創新藥尋突圍,「自研+引入」雙軌戰略能否重塑增長極?","url":"https://stock-news.laohu8.com/highlight/detail?id=2570035010","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570035010?lang=zh_tw&edition=fundamental","pubTime":"2025-09-26 12:59","pubTimestamp":1758862756,"startTime":"0","endTime":"0","summary":"与此同时,2025年第二季度中国创新药对外BD首付款金额高达17.3亿美元,远超同期中国生物医药投融资金额6.9亿美元。根据药智网公布的数据,创新药从临床试验Ⅰ期到批准上市的可能性为12.69%,而整体研发成功率则更低。BD合作已成为创新药研发投入的新资金来源和主要资金来源。柳丹指出,未盈利创新药企需多元融资保障生存。今年上半年全球医药交易TOP10中,中国创新药资产的贡献率超过80%,且交易金额最高的资产也来自国内药企。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250926130238a4450c27&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250926130238a4450c27&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LEGN","BK4505","BK4588","ORR","BK4585","BK4139","02142"],"gpt_icon":0},{"id":"2570021518","title":"腫瘤耐藥治療賽道破局者:應世生物赴港IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2570021518","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570021518?lang=zh_tw&edition=fundamental","pubTime":"2025-09-26 09:36","pubTimestamp":1758850588,"startTime":"0","endTime":"0","summary":"随着公司核心产品逐步接近商业化阶段,其价值释放也将进入关键时期。","market":"fut","thumbnail":"https://img2.gelonghui.com/b17e2-8a06d7ec-2f52-4dea-b0dc-4854d049c415.jpg?guru_height=720&guru_width=1280&guru_size=154189","type":0,"news_type":0,"thumbnails":["https://img2.gelonghui.com/b17e2-8a06d7ec-2f52-4dea-b0dc-4854d049c415.jpg?guru_height=720&guru_width=1280&guru_size=154189"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/2905460","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK1161","LU0456854461.SGD","BK4007","ORR","CRC","LU0266512127.USD","PROC","BK4213","06978","BK1574"],"gpt_icon":0},{"id":"2569066092","title":"盛諾基淫羊藿素軟膠囊新增治療胰腺癌適應症獲臨牀批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2569066092","media":"中金财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569066092?lang=zh_tw&edition=fundamental","pubTime":"2025-09-22 14:37","pubTimestamp":1758523030,"startTime":"0","endTime":"0","summary":"9月19日,北京盛诺基医药科技股份有限公司旗下子公司北京珅诺基医药科技有限公司收到国家药品监督管理局药品审评中心核准签发的《药物临床试验批准通知书》,由北京珅诺基医药科技有限公司申报的淫羊藿素软胶囊新增联合注射用紫杉醇和注射用盐酸吉西他滨用于治疗局部晚期不可切除或转移性胰腺癌。 胰腺癌被称为 “癌中之王”, 5年生存率不足10%。这一研究成果表明其在联合化疗治疗胰腺癌方面具有巨大潜力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20250922/31662587.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1574","09939","BK1515","BK1161","ORR"],"gpt_icon":0},{"id":"2567153639","title":"重大突破!中國這款新藥,中美官方都認定有突破性療效!世界肺癌大會沸騰了","url":"https://stock-news.laohu8.com/highlight/detail?id=2567153639","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567153639?lang=zh_tw&edition=fundamental","pubTime":"2025-09-14 16:56","pubTimestamp":1757840160,"startTime":"0","endTime":"0","summary":" 一种中国原创新药,已被美国食品药品监督管理局授予1项突破性疗法认定,同时还被中国药监局授予6项突破性疗法认定。近期,其在肺癌治疗方向展现出的优势和潜力惊艳亮相2025年世界肺癌大会,并引发全球关注。另一项单药研究临床数据还显示,iza-bren单个药物的治疗效果,也为肺癌患者带来了治疗获益新突破。 中国创新药企从“跟跑”到“领跑”,正在重塑全球肺癌治疗格局。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2025-09-14/doc-infqnexi5513398.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-09-14/doc-infqnexi5513398.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","06978","BK1161","688506","ORR","BK0239"],"gpt_icon":0},{"id":"2566577876","title":"百利天恆iza-bren雙抗ADC獲WCLC雙重認可 一線治療EGFR突變肺癌ORR達100%","url":"https://stock-news.laohu8.com/highlight/detail?id=2566577876","media":"金融界","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566577876?lang=zh_tw&edition=fundamental","pubTime":"2025-09-09 11:19","pubTimestamp":1757387949,"startTime":"0","endTime":"0","summary":"2025年世界肺癌大会上,百利天恒自主研发的iza-bren双抗ADC药物治疗EGFR突变肺癌的两项研究结果获选官方新闻发布计划并进行口头报告。iza-bren作为EGFR×HER3双抗ADC药物,在两项研究中均显示出显著的治疗效果,其中联合奥希替尼的一线治疗方案实现了100%的客观缓解率,单药治疗的中位无进展生存期达到12.5个月。研究结果显示,iza-bren单药治疗取得历史性突破,疗效优势覆盖所有EGFR突变亚组。","market":"us","thumbnail":"https://imgcloud.jrjimg.cn/2025/09/20250909112005475.jpg","type":0,"news_type":0,"thumbnails":["https://imgcloud.jrjimg.cn/2025/09/20250909112005475.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/09/09111953011253.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK4080","ORR","688506","BK0239","BK4231","ADC"],"gpt_icon":0},{"id":"2563320041","title":"宗艾替尼在華獲批 用於非小細胞肺癌治療","url":"https://stock-news.laohu8.com/highlight/detail?id=2563320041","media":"新京报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563320041?lang=zh_tw&edition=fundamental","pubTime":"2025-08-29 17:52","pubTimestamp":1756461162,"startTime":"0","endTime":"0","summary":"8月29日,国家药品监督管理局发布公告,附条件批准宗艾替尼片上市,用于治疗存在HER2(ERBB2)激活突变且既往接受过至少一种系统治疗的不可切除的局部晚期或转移性非小细胞肺癌成人患者。肺癌是全球致死率最高的一类恶性肿瘤,预计到2040年全球发病数将突破300万例。其中,非小细胞肺癌是最常见的病理类型。该疾病确诊时通常已届晚期,患者5年生存率不足30%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202508293499506757.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202508293499506757.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4211","ORR","PFS","BK4195"],"gpt_icon":0},{"id":"2562085777","title":"百億美元BD大藥,國內還有高手","url":"https://stock-news.laohu8.com/highlight/detail?id=2562085777","media":"生物制药小编","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562085777?lang=zh_tw&edition=fundamental","pubTime":"2025-08-28 09:20","pubTimestamp":1756344024,"startTime":"0","endTime":"0","summary":"根据协议,辉瑞将支付12.5亿美元不可退还且不可抵扣的首付款,整个交易的总金额将超过60亿美元。这是国产创新药对外BD的交易中,首次有超过10亿美元的首付款出现,彻底刷新了行业纪录。事实上,这不是中国药企对外BD授权的第一款PD-1/VEGF管线。仅仅这两笔交易,总金额已经超过了100亿美元,PD-1/VEGF这个靶点的魅力可见一斑。这个领域,还有高手。因此,完全有理由对这款已经在美国启动Ⅱ期临床的PD-1/VEGF双抗的潜在BD交易,保持期待。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250828094030a7002c49&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250828094030a7002c49&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TME","LU1023057109.AUD","BK4526","LU1244550221.USD","LU0359202008.SGD","IE00BVYPNV92.GBP","IE00B42XCP33.USD","BK4108","LU1674673691.USD","IE00B1BXHZ80.USD","IE00BYQNZ168.SGD","LU1223082519.USD","BK4548","LU0823417737.USD","01698","LU2237443622.USD","LU1066053197.SGD","LU1430594728.SGD","LU1221951046.USD","IE00B3PB1722.GBP","CSCO","BK4535","LU1506573853.SGD","LU0942090050.USD","IE00BYTNYN87.SGD","LU2039709279.SGD","LU1599440770.SGD","LU0203345920.USD","SG9999015945.SGD","SG9999015952.SGD","LU1880398471.USD","LU1894683264.USD","LU2237443978.SGD","LU1223083913.SGD","BK4560","BK4571","LU0889566641.SGD","BK4531","CDE","LU1778281490.HKD","ORR","SG9999001440.SGD","BK4515","IE00BZ1G4Q59.USD","LU1046421795.USD","LU0731783394.SGD","SG9999011746.SGD","IE00BKVL7J92.USD","LU2506951875.HKD","LU2237443465.HKD"],"gpt_icon":0},{"id":"2562225263","title":"諾誠健華的下一個黃金十年","url":"https://stock-news.laohu8.com/highlight/detail?id=2562225263","media":"生物制药小编","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562225263?lang=zh_tw&edition=fundamental","pubTime":"2025-08-25 09:21","pubTimestamp":1756084899,"startTime":"0","endTime":"0","summary":"目前来看,诺诚健华不断兑现全年预期,向着年度目标大踏步前进。站在十周年的新起点,诺诚健华将以小分子奥布替尼和大分子坦昔妥单抗的商业化作为支点,持续加码创新管线与国际化布局,稳步迈向更具全球影响力的下一个十年。为了加快国际化进程,诺诚健华计划采取一系列有力举措。目前,诺诚健华正开展多项国际多中心临床试验,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250825100546a49c8b03&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250825100546a49c8b03&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4199","AD","ITP","ORR","BK4132"],"gpt_icon":0},{"id":"2561233133","title":"德達博妥單抗在華獲批新適應症,用於晚期乳腺癌治療","url":"https://stock-news.laohu8.com/highlight/detail?id=2561233133","media":"新京报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2561233133?lang=zh_tw&edition=fundamental","pubTime":"2025-08-23 14:25","pubTimestamp":1755930309,"startTime":"0","endTime":"0","summary":"8月22日,国家药监局正式批准注射用德达博妥单抗(中文商品名:达卓优)新适应症,用于治疗既往接受过内分泌治疗且在晚期疾病阶段接受过至少一线化疗的不可切除或转移性的激素受体(HR)阳性、(HER2)阴性乳腺癌成人患者。此次获批是基于TROPION-Breast01全球Ⅲ期研究的积极结果。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202508233492620351.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202508233492620351.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["ORR","BK4080","BK4195","PFS","HR","BK4211","BK4231","BK4225","BK4203","ADC"],"gpt_icon":0},{"id":"2560382100","title":"創新成果逐步兑現,全球化佈局潛力可期","url":"https://stock-news.laohu8.com/highlight/detail?id=2560382100","media":"东方财富","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560382100?lang=zh_tw&edition=fundamental","pubTime":"2025-08-20 10:30","pubTimestamp":1755657059,"startTime":"0","endTime":"0","summary":"经营分析加速创新成果兑现,上半年多项里程碑创国内首次纪录。国际化进程行稳致远,后续出海合作潜力可期。全球PMS患者基数庞大、达到290万人,而目前治疗手段匮乏、属于蓝海市场,奥布替尼海外合作潜力巨大。其中ICP-332治疗特应性皮炎的III期临床试验预计今年完成患者入组,治疗白癜风的II/III期临床试验正在加速推进中,治疗结节性痒疹的全球II期临床即将启动。ICP-332进度领先,全球合作潜力大。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202508201031029752eb09&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202508201031029752eb09&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ORR"],"gpt_icon":0},{"id":"2560143840","title":"榮昌生物:國家藥監局授予RC148突破性治療藥物認定用於治療非小細胞肺癌(NSCLC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2560143840","media":"格隆汇","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560143840?lang=zh_tw&edition=fundamental","pubTime":"2025-08-19 17:28","pubTimestamp":1755595680,"startTime":"0","endTime":"0","summary":"格隆汇8月19日丨荣昌生物发布公告,公司原研的新型双特异性抗体RC148被中国国家药品监督管理局药品审评中心正式纳入突破性治疗药物品种,针对适应症为:RC148联合多西他赛治疗经PD-1/PD-L1抑制剂和含铂化疗治疗失败的驱动基因阴性局部晚期或转移性非小细胞肺癌。对纳入突破性治疗药物的创新药,CDE将优先配置资源,新药上市时间将大大缩短。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250819172958a6eed188&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250819172958a6eed188&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ORR","CDE","LU1223082519.USD","BK4017","LU1223083913.SGD","LU1223082196.USD"],"gpt_icon":0},{"id":"2560216357","title":"2025年(H1)MNC研發動向全景:技術迭代與結構重塑下的新格局","url":"https://stock-news.laohu8.com/highlight/detail?id=2560216357","media":"药智网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560216357?lang=zh_tw&edition=fundamental","pubTime":"2025-08-19 14:53","pubTimestamp":1755586401,"startTime":"0","endTime":"0","summary":"反观MNC的研发策略调整,其年度动向既映射着全球医药创新趋势,也为国内生物技术企业的对外合作提供了关键指引。后者为靶向CD38的单克隆抗体,因治疗中断率高达51.1%,而被放弃全球权益。辉瑞:调转船头,押注下一代抗肿瘤疗法2025年8月5日,辉瑞公布了最新半年报,期间营收283.7亿美元,同比增长仅1%。管线调整上,期间礼来共终止了4个临床项目:2025上半年礼来终止临床研究数据来源:药智数据","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250819150212a6ee83c3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250819150212a6ee83c3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1571399168.USD","BK4532","LU0868494617.USD","PFE","BK4534","LU1023059063.AUD","LU1066051498.USD","IE00BLSP4452.SGD","LU1430594728.SGD","LU2361044865.SGD","LU0965508806.USD","LU1941712264.USD","SGXZ57979304.SGD","IE0009355771.USD","IE000M9KFDE8.USD","LU1699723380.USD","SG9999014567.USD","LU1061106388.HKD","LU1066053197.SGD","LU1894683348.USD","LU0965509101.SGD","LU0058720904.USD","ORR","IE00BJT1NW94.SGD","LU0154236417.USD","LU1037948897.HKD","LU1162221912.USD","LU1989772840.SGD","LU1093756325.SGD","LU0211331839.USD","IE00BBT3K403.USD","LU0289739699.SGD","NVO","LU0321505868.SGD","LU0208291251.USD","IE00BJJMRZ35.SGD","LU0122379950.USD","LU0321505439.SGD","BK4007","LU1291159041.SGD","MRK","IE0002270589.USD","SG9999015358.SGD","LU0320765489.SGD","LU0170899867.USD","LU0106261372.USD","LU1989771016.USD","LU1066051225.USD","IE00BZ1G4Q59.USD","LU1989772923.USD"],"gpt_icon":1},{"id":"2559998438","title":"基石藥業2025年中期業績公告:創新管線加速推進,價值潛力凸顯","url":"https://stock-news.laohu8.com/highlight/detail?id=2559998438","media":"基石药业官微","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559998438?lang=zh_tw&edition=fundamental","pubTime":"2025-08-14 19:18","pubTimestamp":1755170293,"startTime":"0","endTime":"0","summary":"截至2025年6月30日,现金与现金等价物及定期存款合计为人民币6.528亿元。此外,公司于2025年7月完成配售,所得款项净额约为人民币4.2579亿元。业务摘要截至2025年6月30日止6个月及截至本公告日期,我们加速全球商业化扩张战略,推进差异化管线,并通过战略合作伙伴关系强化我们的商业版图。2025年7月,与Gentili在西欧23个国家及英国达成战略合作。国家医保目录谈判准备2025年8月,普拉替尼已通过2025年NRDL谈判的形式审查。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250814195152a4888af4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250814195152a4888af4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4097","BK4195","BK4211","PD","LU2463526074.USD","ASH","LU1169590202.USD","ADC","BK4181","BK4231","BK4218","PFS","BK4107","OS","BK4080","BK4081","BK4213","BK4588","LU0053666078.USD","ORR","PK","BK4023","BK4109","LU0210528500.USD","CRT","L","LU1169589451.USD","EMA","BK4585","LU2487616109.SGD"],"gpt_icon":0},{"id":"2559939888","title":"大行評級|花旗:大幅上調復宏漢霖目標價至95港元 評級升至「買入」","url":"https://stock-news.laohu8.com/highlight/detail?id=2559939888","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559939888?lang=zh_tw&edition=fundamental","pubTime":"2025-08-14 12:31","pubTimestamp":1755145915,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU0106831901.USD","LU0162691827.USD","LU1162221912.USD","LU1267930227.SGD","LU1366192091.USD","LU2125154935.USD","ORR","LU0980610538.SGD","LU0098860793.USD","LU1244550494.USD","LU0320765646.SGD","LU0170899867.USD","LU2236285917.USD","BK4566","LU0128525689.USD","BK4504","LU0130102774.USD","LU1668664300.SGD","BK4534","LU0477156953.USD","LU2360032135.SGD","LU1244550221.USD","LU2417539215.USD","LU2456880835.USD","BK4588","BK7095","LU1201861249.SGD","LU2462157665.USD","LU0072461881.USD","LU1791807156.HKD","LU2125154778.USD","BK4559","BK4585","02696","LU0648001328.SGD","BK4207","BK1161","IE00BSNM7G36.USD","LU0130517989.USD","LU0052756011.USD","LU1244550577.SGD","LU0310800965.SGD","ORR.AU"],"gpt_icon":0},{"id":"2559998046","title":"復宏漢霖三款創新爆品集中亮相WCLC,出擊肺癌全類型治療最前沿","url":"https://stock-news.laohu8.com/highlight/detail?id=2559998046","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559998046?lang=zh_tw&edition=fundamental","pubTime":"2025-08-14 08:36","pubTimestamp":1755131782,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4023","BK1161","159992","BK4080","ORR","BK1574","BK4195","BK4231","BK4211","LU1169590202.USD","06978","LU1169589451.USD","ADC","02696","PFS","PD"],"gpt_icon":0},{"id":"2559965966","title":"同源康醫藥-B:EGFR靶向創新藥艾多替尼在腦轉移肺癌患者中展現突破性療效——WCLC 2025公佈ESAONA關鍵註冊研究中期結果","url":"https://stock-news.laohu8.com/highlight/detail?id=2559965966","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559965966?lang=zh_tw&edition=fundamental","pubTime":"2025-08-14 07:24","pubTimestamp":1755127440,"startTime":"0","endTime":"0","summary":"艾多替尼片是同源康医药开发的高选择性小分子抑制剂,以经典EGFR 基因突变为靶点,旨在满足在当前治疗标准下对非小细胞肺癌脑转移瘤尚未得到满足的临床需求。最终完成数据分析将用于向NMPA申请艾多替尼片的完全上市批准。截至2025年2月28日,研究共入组257例EGFR突变型NSCLC存在脑转移患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250814072651a6e4aa40&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250814072651a6e4aa40&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ORR","PFS","BK4195","OS","BK4097","BK4211"],"gpt_icon":0},{"id":"2558965407","title":"業績終迎拐點,股價卻微跌,資本在擔心什麼?","url":"https://stock-news.laohu8.com/highlight/detail?id=2558965407","media":"CPHI制药在线","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558965407?lang=zh_tw&edition=fundamental","pubTime":"2025-08-11 18:06","pubTimestamp":1754906785,"startTime":"0","endTime":"0","summary":"8月6日,百济神州公布2025年第二季度及上半年业绩。但百济神州的盈利首秀却未换来资本市场的积极回应:业绩发布当日,公司美股跌2.84%,A股跌4.02%、港股微跌0.11%。资本到底在担心什么?2020年6月,泽布替尼在国内获NMPA批准上市。阿可替尼于2017年获FDA批准上市,用于MCL的二线治疗。在美国“通胀消减法案”纳入的第一批药品中,伊布替尼赫然在列,并且将降价38%,于2026年1月1日起执行。届时,泽布替尼将不得不卷入这场价格战。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250811190257a6df7de4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250811190257a6df7de4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PFS","LU0347712357.USD","BK4588","LU2229751404.USD","LU1623119135.USD","WM","BK4533","LU0289961442.SGD","BK4107","BK4526","CR","LU1721428933.USD","BK4211","ONC","L","LU2125910336.SGD","BK4566","LU0689626769.HKD","LU0057025933.USD","LU1892829315.USD","BK4585","BK4534","LU2092937221.SGD","LU0124676726.USD","LU1585245621.USD","LU2298064838.USD","LU2413666699.HKD","LU1712237335.SGD","LU1923621640.USD","LU2041044095.USD","FL","06160","LU2023250504.SGD","LU0069063385.USD","LU0053666078.USD","LU2487616109.SGD","LU0210528500.USD","688235","BK4195","LU1989772923.USD","LU2023250843.SGD","LU2125910179.SGD","LU1974910355.USD","LU1430594728.SGD","ORR","BK4120","BK4094","LU1939255532.USD","LU1989772840.SGD","BK4161","LU2362541513.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":46,"code":"91000000","status":"200"}]}}